This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEC0E0NI_M.jpg
MMEDF’s stock has gained 31.8% year-to-date on the back of growing acceptance of psychedelic drugs for treating mental disorders.
However, none of its major projects has yet generated revenue or profit. And given that MMEDF is still in the early stages of its lifecycle, we think the stock could be a risky buy currently.
